Amivantamab Plus Lazertinib Overall Survival Benefit in First-Line EGFR-Mutated NSCLC

Elizabeth Dennis, MSN, APRN, FNP-C, explains how overall survival data from the MARIPOSA trial, which compared amivantamab plus lazertinib with osimertinib monotherapy, changed the first-line conversation for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. She notes that amivantamab plus lazertinib demonstrated an overall survival benefit, shifting the goal of treatment from delaying progression to helping patients live longer. Ms. Dennis emphasizes individualizing treatment and considers amivantamab plus lazertinib for patients who are appropriate for combination therapy and willing and able to manage additional monitoring and potential toxicities. When counseling patients, she explains that more intensive treatment may offer greater benefit along with additional side effects. She describes the goal as helping patients live longer and live well during treatment, with advanced practice providers (APPs) central to that effort. “APPs play a significant role in educating patients, identifying toxicities early, and supporting safe treatment continuation,” Ms. Dennis says.